Kamada (KMDA) Earning Somewhat Favorable Media Coverage, Study Finds
Media coverage about Kamada (NASDAQ:KMDA) has trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kamada earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.0041710624686 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern’s scoring:
- BRIEF-Kamada announces new supply agreement with international organization for KamRAB (KMDA) (markets.businessinsider.com)
- Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection (finance.yahoo.com)
- Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages (americanbankingnews.com)
- Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA) (americanbankingnews.com)
- Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (finance.yahoo.com)
Several brokerages have recently weighed in on KMDA. Zacks Investment Research cut Kamada from a “hold” rating to a “strong sell” rating in a report on Thursday, November 16th. TheStreet cut Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price (down from $9.00) on shares of Kamada in a report on Wednesday, August 2nd. Finally, ValuEngine cut Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.50.
Kamada (NASDAQ KMDA) traded down $0.05 on Friday, reaching $4.65. The company had a trading volume of 14,600 shares, compared to its average volume of 71,525. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.73 and a current ratio of 3.71.
ILLEGAL ACTIVITY WARNING: “Kamada (KMDA) Earning Somewhat Favorable Media Coverage, Study Finds” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/kamada-kmda-earning-somewhat-favorable-media-coverage-study-finds/1724279.html.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.